322 related articles for article (PubMed ID: 30337279)
21. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses.
Kortylewski M; Swiderski P; Herrmann A; Wang L; Kowolik C; Kujawski M; Lee H; Scuto A; Liu Y; Yang C; Deng J; Soifer HS; Raubitschek A; Forman S; Rossi JJ; Pardoll DM; Jove R; Yu H
Nat Biotechnol; 2009 Oct; 27(10):925-32. PubMed ID: 19749770
[TBL] [Abstract][Full Text] [Related]
22. The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer.
Choi SY; Xue H; Wu R; Fazli L; Lin D; Collins CC; Gleave ME; Gout PW; Wang Y
Clin Cancer Res; 2016 Jun; 22(11):2721-33. PubMed ID: 26755530
[TBL] [Abstract][Full Text] [Related]
23. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
Yu C; An M; Li M; Liu H
Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
[TBL] [Abstract][Full Text] [Related]
24. The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo.
Tian Y; Li M; Yu C; Zhang R; Zhang X; Huang R; Lu L; Yuan F; Fan Y; Zhou B; Men K; Xu H; Yang L
Oncotarget; 2017 Jul; 8(28):45951-45964. PubMed ID: 28515346
[TBL] [Abstract][Full Text] [Related]
25. Myeloid STAT3 Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance into Tumor-Promoting Inflammation.
Zhou J; Qu Z; Sun F; Han L; Li L; Yan S; Stabile LP; Chen LF; Siegfried JM; Xiao G
Cancer Immunol Res; 2017 Mar; 5(3):257-268. PubMed ID: 28108629
[TBL] [Abstract][Full Text] [Related]
26. Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity.
Bourquin C; Anz D; Zwiorek K; Lanz AL; Fuchs S; Weigel S; Wurzenberger C; von der Borch P; Golic M; Moder S; Winter G; Coester C; Endres S
J Immunol; 2008 Sep; 181(5):2990-8. PubMed ID: 18713969
[TBL] [Abstract][Full Text] [Related]
27. Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy.
Kortylewski M; Kujawski M; Herrmann A; Yang C; Wang L; Liu Y; Salcedo R; Yu H
Cancer Res; 2009 Mar; 69(6):2497-505. PubMed ID: 19258507
[TBL] [Abstract][Full Text] [Related]
28. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells.
Shirota Y; Shirota H; Klinman DM
J Immunol; 2012 Feb; 188(4):1592-9. PubMed ID: 22231700
[TBL] [Abstract][Full Text] [Related]
29. MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Hernandez-Hoyos G; Sewell T; Bader R; Bannink J; Chenault RA; Daugherty M; Dasovich M; Fang H; Gottschalk R; Kumer J; Miller RE; Ravikumar P; Wiens J; Algate PA; Bienvenue D; McMahan CJ; Natarajan SK; Gross JA; Blankenship JW
Mol Cancer Ther; 2016 Sep; 15(9):2155-65. PubMed ID: 27406985
[TBL] [Abstract][Full Text] [Related]
30. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
[TBL] [Abstract][Full Text] [Related]
31. Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma.
Zhou B; Yan J; Guo L; Zhang B; Liu S; Yu M; Chen Z; Zhang K; Zhang W; Li X; Xu Y; Xiao Y; Zhou J; Fan J; Hung MC; Li H; Ye Q
Theranostics; 2020; 10(14):6530-6543. PubMed ID: 32483468
[TBL] [Abstract][Full Text] [Related]
32. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.
Molavi O; Ma Z; Hamdy S; Lai R; Lavasanifar A; Samuel J
Immunol Cell Biol; 2008; 86(6):506-14. PubMed ID: 18392040
[TBL] [Abstract][Full Text] [Related]
33. STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer.
Oweida AJ; Darragh L; Phan A; Binder D; Bhatia S; Mueller A; Court BV; Milner D; Raben D; Woessner R; Heasley L; Nemenoff R; Clambey E; Karam SD
J Natl Cancer Inst; 2019 Dec; 111(12):1339-1349. PubMed ID: 30863843
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of
Odate S; Veschi V; Yan S; Lam N; Woessner R; Thiele CJ
Clin Cancer Res; 2017 Apr; 23(7):1771-1784. PubMed ID: 27797972
[No Abstract] [Full Text] [Related]
35. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
36. Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4
Gallotta M; Assi H; Degagné É; Kannan SK; Coffman RL; Guiducci C
Cancer Res; 2018 Sep; 78(17):4943-4956. PubMed ID: 29945961
[TBL] [Abstract][Full Text] [Related]
37. Combined treatment targeting HIF-1α and Stat3 is a potent strategy for prostate cancer therapy.
Reddy KR; Guan Y; Qin G; Zhou Z; Jing N
Prostate; 2011 Dec; 71(16):1796-809. PubMed ID: 21480310
[TBL] [Abstract][Full Text] [Related]
38. CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3.
Liang M; Zhan F; Zhao J; Li Q; Wuyang J; Mu G; Li D; Zhang Y; Huang X
BMC Cancer; 2016 Jul; 16():504. PubMed ID: 27435207
[TBL] [Abstract][Full Text] [Related]
39. Local CpG-
Zhang C; Huang R; Ren L; Song J; Kortylewski M; Swiderski P; Forman S; Yu H
bioRxiv; 2023 Aug; ():. PubMed ID: 37645787
[TBL] [Abstract][Full Text] [Related]
40. Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling.
Xiang P; Jin S; Yang Y; Sheng J; He Q; Song Y; Yu W; Hu S; Jin J
Prostate; 2019 Jun; 79(9):1018-1031. PubMed ID: 31018021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
